Kristin Peck is Chief Executive Officer of Zoetis, the world’s leading animal health company and a member of the Fortune 500. Ms. Peck is also a member of the Zoetis Board of Directors.
Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis. Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in many roles at the company, including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research.
Before joining Zoetis, Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. In this role, she was responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses, paving the way for a public animal health company and attractive investment opportunity.
Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck is on the Board of BlackRock, the world’s largest asset management firm. She is also a member of the Business Roundtable and a Board member of Catalyst, a global non-profit that helps companies around the world accelerate women into leadership. In addition, she serves on the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. Named by Barron’s as one of the top CEOs in 2022, and by Fortune as a 2020 Businessperson of the Year, Ms. Peck has been recognized for her leadership and Zoetis' strong performance in challenging times.
Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School.